Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory…

NEWPORT, United Kingdom and AMSTERDAM, July 21, 2021 (GLOBE NEWSWIRE) -- Nanopharm Ltd., an Aptar Pharma company and leader in contract research and development of orally inhaled and nasally delivered drug products (OINDP) and Leyden Labs, a company targeting commonalities of viral families to protect humanity from known and future viruses, today announced that they have entered into an agreement to develop nasal sprays that may provide broad protection against respiratory viruses, combining Leyden Labs’ portfolio and Nanopharm’s expertise in the development of nasally delivered drug products.

More here:
Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory...

Related Post